Anthropic launches AI drug discovery program, joining tech giants in betting on healthcare (3 minute read)
Summary
Anthropic is launching an internal AI drug discovery program to develop treatments for neglected diseases, aiming to improve its AI tools for drugmakers and join tech giants in the healthcare market.
View Cached Full Text
Cached at: 07/01/26, 05:19 PM
Similar Articles
Anthropic wants to develop its own drugs
Anthropic announced Claude Science, an AI workbench for scientists, and revealed its own plans to develop drugs for neglected diseases using AI, entering a competitive field of AI-driven drug discovery.
Anthropic Veterans' Startup Seeks to Help Scientists Develop Their Own AI (5 minute read)
Mirendil, a startup founded by Anthropic veterans, raised $200 million in seed funding to develop and distribute AI tools that accelerate AI research for everyone.
Anthropic
Anthropic, the AI safety and research company, is in the news.
Jul 20, 2026AnnouncementsApply for Anthropic’s AI for Science rare disease research grants
Anthropic announces a focused call for rare disease research grants under their AI for Science program, offering up to $50,000 in Claude credits to researchers and early-stage biotechs.
Ahead of its IPO, Anthropic’s Daniela Amodei shrugs off doubts about AI’s returns
Anthropic is moving toward a public IPO filing after raising $65 billion at a $965 billion valuation, with co-founder Daniela Amodei citing the need for capital to train frontier models and serve inference at scale. The company reported $47 billion in annualized revenue as of May 2026, and has partnered with xAI for $1.25 billion per month in compute capacity rather than building its own data centers.